September 25th 2023
C. Ola Landgren, MD, PhD, discussed the ASCENT trial and his predictions for future developments in the myeloma space.
During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, explained the research he and others conducted leading to the development of tagraxofusp-erzs to treat patients with blastic plasmacytoid
dendritic cell neoplasm.
September 9th 2023
Evolving research has now shown that immunotherapies can be combined with one another and used to specifically target the cancer cells.
In an interview with Targeted Oncology, Amer Zeidan, MBBS, discussed the IMerge study and next steps for imetelstat for patients with lower-risk MDS.
September 8th 2023
In the third article of this series, Eytan M. Stein, MD, discusses the treatment landscape for patients with lower-risk MDS and reviews follow-up data from the IMerge clinical trial.
Treatment Paradigm for Myelofibrosis
A review of the treatment armamentarium for patients with myelofibrosis in the context of clinical trial data supporting use of these agents.
Identifying the Categories of Myelofibrosis
Shifting their attention to myelofibrosis, Rami S. Komrokji, MD, and Pankit Vachhani, MD, define differences between various subsets of disease.
Patient Case 3: A 57-Year-Old Man With Relapsed BPDCN
Centering discussion on the third patient case, panelists review second-line therapy options for those who relapse with blastic plasmacytoid dendritic cell neoplasm.
Exploring the Background and Clinical Presentation of BPDCN
During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the clinical presentation of blastic plasmacytoid dendritic cell neoplasm and how it came to be recognized as a distinct rare hematologic malignancy.
This is the first of 2 articles based on this event.
Patient Case 2: A 22-Year-Old Woman With BPDCN
Expert panelists review the case of a 22-year-old woman diagnosed with BPDCN and consider the role of first-line chemotherapy in this setting.
Novel Therapies Being Investigated in Polycythemia Vera
Before closing out their review of polycythemia vera management, expert hematologist-oncologists highlight novel therapies in the pipeline.
Factors in Selecting Optimal First-Line Therapy for BPDCN
Closing out their discussion on the first patient case of BPDCN, panelists consider which factors best inform the optimal selection of frontline therapy.
Selecting and Sequencing Therapy in Patients With Polycythemia Vera
Considerations for the selection of optimal therapy in patients with polycythemia vera, and how these novel agents may be sequenced in the event of disease progression.
Management of Capillary Leak Syndrome in BPDCN
A brief review of the identification and management of capillary leak syndrome in patients being treated for blastic plasmacytoid dendritic cell neoplasm.
A Role for Tagraxofusp in First-Line Setting in BPDCN
Expert perspectives on the first-line use of tagraxofusp, a CD123-directed therapy, in patients with blastic plasmacytoid dendritic cell neoplasm.
Treatment Armamentarium for Polycythemia Vera
Centering discussion on polycythemia vera, Rami S. Komrokji, MD, and Pankit Vachhani, MD, share an in-depth review of cornerstone therapies in this setting.
Important Pathways and Biomarkers in Myeloproliferative Neoplasms
Expert hematologist-oncologists share insight on the pathways driving myeloproliferative neoplasms and biomarkers that may be targeted with novel therapy.
Luspatercept Improves RBC Transfusion Independence in Patients With MDS
In the prespecified interim analysis of the COMMANDS trial for low-risk myelodysplastic syndromes, luspatercept had statistically significant and clinically meaningful improvements in red blood cell transfusion independence with no new safety signals.
Patient Case 1: A 71-Year Old Man With BPDCN
Centering discussion on the first patient case of BPDCN, expert panelists highlight various assessment tools that may help overcome barriers to an early diagnosis.
Identification and Classification of BPDCN
Shared insight on methods to identify blastic plasmacytoid dendritic cell neoplasm followed by updated classifications from the World Health Organization.
Myeloproliferative Neoplasms: Testing, Workup, and Diagnosis
Broad perspective on diagnosis of the myeloproliferative neoplasms via optimal workup and molecular testing.
Overview of Myeloproliferative Neoplasms
A comprehensive overview of myeloproliferative neoplasms followed by insight on the differences between essential thrombocytopenia, polycythemia vera, and myelofibrosis.
Treatment Options Continue to Expand, Improving Survival Rates in ALL
In an interview with Targeted Oncology, Nicholas J. Short, MD, discussed the evolution of the treatment landscape for acute lymphoblastic leukemia and what he hopes is next to come.
Exploring Non-Intensive Treatment Options for Elderly/ Unfit Patients With AML
In an interview with Targeted Oncology, Tapan M. Kadia, MD, discussed the changes seen in the treatment landscape for patients with acute myeloid leukemia, specifically highlighting elderly and/or unfit patients.
Classification, Treatment, and Supportive Care Options in AML
At the 2022 NCCN: Hematologic Malignancies Conference, a panel discussion gave an overview of current treatment trends for acute myeloid leukemia, as well as supportive care measures to utilize during therapy.
Bispecifics Show Promise Against Hematologic Malignancies
Additional data emerged demonstrating the value of blinatumomab not only in patients with relapsed acute lymphoblastic leukemia but also in those with detectable minimal residual disease.
Early Data of Azacitidine and Venetoclax Shows Potential in High-Risk CML and MDS
Phase 1 results examining azacitidine and venetoclax in high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia elicited an overall response rate of 87%.
Cortes Discusses Changing Landscape of Hematology and Challenges to the Cancer Center of Today
Relapse Less Likely With Orca-T vs Standard Transplant in Hematologic Malignancies
In comparison with conventional transplant options, Orca-T may be more effective with a lower probability of infection in patients with hematologic malignancies.
Using Biology to Determine Type and Duration of Treatment in Waldenström Macroglobulinemia
Jorge J. Castillo, MD, will explore the challenges of managing WM. He will present on September 30, 2022, at 11:04 AM.
Multi-Stage Trial of Tagraxofusp Shows Frontline Efficacy in BPDCN
Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.
Exploring Targeted Therapies in Myelodysplastic Syndromes
Lionel Adès, MD, PhD, discussed emerging targeted therapies for myelodysplastic syndromes during a presentation at the 10th Annual Meeting of the Society of Hematologic Oncology.
MDS Setting Looking to BCL2 Inhibitors for Improved Survival, Sequencing Options
Combinations of the BCL2 inhibitor venetoclax with hypomethylating agents are undergoing investigation to determine benefit in high-risk myelodysplastic syndrome.
Debating the Significance of MRD in Blood Cancers vs Initial Patient Characteristics
In the myeloma space, minimal residual disease negativity is prognostic of progression-free survival in relapsed or refractory patients. In leukemia, the biomarker combined with other prognostication techniques provides complex information that is clinically relevant.
Garcia-Manero Calls for New Combination Approaches in MDS
An overview of the single-cell level in early stage disease and describe new molecular classifications of myelodysplastic syndrome.
2 Clarke Drive Cranbury, NJ 08512